2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Publié dansEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 7, p. 2121-2139
Date de publication2021-07
Date de mise en ligne2021-03-05
Résumé
Mots-clés
- Alzheimer’s disease
- Aβ42
- CSF
- P-tau
- T-tau
- Strategic roadmap
- Alzheimer Disease / diagnosis
- Amyloid beta-Peptides
- Biomarkers
- Humans
- Peptide Fragments
- Tau Proteins
Citation (format ISO)
LEUZY, A et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 7, p. 2121–2139. doi: 10.1007/s00259-021-05258-7
Fichiers principaux (1)
Article (Published version)
Fichiers secondaires (1)
Identifiants
- PID : unige:160857
- DOI : 10.1007/s00259-021-05258-7
- PMID : 33674895
- PMCID : PMC8175301
ISSN du journal1619-7070